$DFTX Definium Therapeutics (NASDAQFTX) Stock Price Expected to Rise, HC Wainwright Analyst Says Definium Therapeutics (NASDAQFTX - Get Free Report) had its price objective hoisted by investment analysts at HC Wainwright from $55.00 to $70.00 in a research note issued on Monday,Benzinga reports. The firm presently has a "buy" rating on the stock. HC Wainwright's target price points to a potential upside of 301.15% from the company's current price. https://www.marketbeat.com/instant-...o-rise-hc-wainwright-analyst-says-2026-03-02/
DT-402 will make $DFTX a 20B company long term after DT-120 is approved. If a treatment could improve social functioning or learning, it could potentially reduce the number of therapy hours required over time. https://www.wsj.com/health/healthca...aa435?st=DYgYyH&reflink=article_copyURL_share @WSJbusiness @WSJhealth @WSJmarkets
GOP Senator To File Bill Promoting Psychedelics Research And Treatment For Veterans https://www.marijuanamoment.net/gop...hedelics-research-and-treatment-for-veterans/
Definium Therapeutics to Host Investor and Analyst Day in New York on April 22, 2026 https://ir.definiumtx.com/news-even...-and-analyst-day-in-new-york-on-april-22-2026
